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Abstract: The synthesis of guanine α-carboxy nucleoside phosphonate (G-α-CNP) is 
described. Two routes provide access to racemic G-α-CNP 9, one via base construction and 
the other utilizing Tsuji–Trost allylic substitution. The latter methodology was also applied to 
the enantiopure synthesis of both antipodes of G-α-CNP, each of which shows interesting 
antiviral DNA polymerase activity. Additionally, we report an improved multi-gram scale 
preparation of the cyclopentene building block 10, starting material for the preferred Tsuji–
Trost route to 9. 
 
Carbocyclic nucleosides have been of interest to medicinal chemists for several decades,
1–3
 
due to their broad spectrum of biological activity and therapeutic importance in the treatment 
of conditions such as cancer,
4
 hepatitis and HIV infections.
5
 Current clinical examples 
include the anti-HIV drug abacavir 1 and entecavir 2, for the treatment of hepatitis B virus 
(HBV) (Figure 1), and interest in the design and synthesis of new carbanucleosides continues 
unabated. We recently reported the synthesis of a new class of nucleoside phosphonate 
analogues, α-carboxy nucleoside phosphonates (α-CNPs), which show potent inhibitory 
activity against HIV-1 reverse transcriptase (RT) without the need for prior (metabolic) 
activation.
6
 This feature of α-CNPs sets them apart from all current nucleoside and nucleotide 
analogue drugs (e.g. tenofovir 3) which require phosphorylation by viral and/or cellular 
kinases in order to become active.
7
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Figure 1. Some nucleoside analogue antivirals (1-3) and T-α-CNP (4) 
The key structural feature of α-CNPs is a carboxyl group at the alpha position of the 
carbocyclic nucleoside phosphonate, as exemplified by thymine CNP (T-α-CNP) 4. 
Crystallographic studies of the interaction between the prototype thymine T-α-CNP and HIV-
1 reverse transcriptase reveal that the carboxylate oxygen and both phosphonate oxygens of 
the CNP chelate to a Mg
2+
 ion (B) at the enzyme active site, in a manner analogous to the 
chelation by α-, β- and γ-phosphate oxygens of the natural dTTP (Figure 2).
8
 Retention of 
Watson-Crick base-pairing leads to specificity not seen with other nucleotide-competing 
reverse transcriptase inhibitors (NcRTIs). With an α-CNP bound at the substrate binding site, 
hydrolysis and incorporation of an incoming dNTP by RT can no longer take place and RT 
inhibition thereby occurs. In this way, α-CNPs act as nucleoside triphosphate mimics and 
behave as NcRTIs. 
 
Figure 2. Binding of T-α-CNP (a) and dTTP (b) at the polymerase active site of HIV-1 RT 
Our original report described the synthesis of α-CNPs containing the nucleobases thymine 4, 
adenine 5, cytosine 6, uracil 7 and 5-fluorouracil 8.
6
 However, initial attempts to prepare the 
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guanine α-CNP 9 using the same methodology had proved unsuccessful. As guanine is a key 
functionality in many drugs we were keen to obtain and evaluate G-α-CNP. Herein we extend 
the series of α-CNPs to include the synthesis of the guanine analogue 9 (Figure 3). 
 
Figure 3. α-Carboxy nucleoside phosphonates (α-CNPs) 
We recently reported the biological activity of G-α-CNP.
9
 The guanine analogue (IC50 : 0.62 
µM) proved to be an equally potent inhibitor of HIV-1 RT as the prototype T-α-CNP (IC50 : 
0.41 µM) with activity residing only in the L-isomer as previously reported for the original 
series of α-CNPs.
8
 However, when herpes virus DNA polymerases (i.e. HSV-1, HCMV) 
were investigated, interestingly both (D)-G-α-CNP and (L)-G-α-CNP were found to inhibit 
herpes DNA polymerases in a non-competitive manner with respect to the natural dNTPs, a 
result indicative of interaction at a location other than the polymerase substrate active site of 
the herpes-encoded enzymes. This variation in inhibition profile across a range of viral 
polymerases is unprecedented and identifies G-α-CNP as an inhibitor of multiple viral DNA 
polymerases, with a different molecular mechanism of inhibition depending on the nature of 
the enzyme.  
Our original strategy for α-CNP synthesis involved O–H insertion of trimethyl 
phosphonodiazoacetate with the widely-used cyclopentene building block 10 followed by 
incorporation of the desired nucleobase using Tsuji–Trost
10,11
 methodology (Figure 4, Route 
I) and was successfully applied to the synthesis of pyrimidine (4,6-8) and adenine (5) α-
CNPs. The convergent approach with late-stage attachment of the nucleobase is attractive 
because base protection is not required. However, Tsuji–Trost allylic substitution proved to 
be capricious: yields were only moderate in general and in the case of purine bases quite 
poor, due to competition between N9- and N7-insertion.
12
 Therefore, when this strategy was 
unsuccessful for the guanine analogue we explored other options. 
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Figure 4. Routes to α-CNPs from 10 and 11 
Several synthetic methodologies can be applied to carbocyclic nucleosides, among them base 
construction from cyclopentyl amines (Figure 4, Route II).
1,2
 In this instance, base 
construction proved effective and a convenient one-pot microwave procedure
13
 was 
employed in the synthesis of racemic guanine α-CNP 9 (Scheme 1). Reaction of cis-3-
aminocyclopentanol 11 with 2-amino-4,6-dichloro-5-formamidopyrimidine afforded the 
hydroxycyclopentylpurine 12 in 72% yield. Temporary TBS protection of the alcohol gave 
13 then Boc protection of the amine afforded 14, which was treated with TBAF to provide 
alcohol 15 required for the O–H insertion step. Reaction of 15 with trimethyl 
phosphonodiazoacetate in the presence of rhodium acetate as catalyst for 16 h at reflux in 
benzene afforded the protected nucleoside phosphonate 16 in 30% yield following careful 
chromatography. As with previous CNPs, 16 was formed as an equimolar mixture of 
diastereomers at the position alpha to the phosphonate. Reaction of 16 with TMSBr in the 
microwave
14
 followed by treatment with aqueous sodium hydroxide removed all protecting 
groups and converted the chloropurine to guanine, thereby providing racemic guanine α-CNP 
9 in 76% yield following charcoal chromatography. 
Scheme 1. Synthesis of (±)-G-α-CNP 9 via base construction 
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This strategy of initial purine base construction followed by late-stage introduction of the 
phosphonate moiety provided access to the racemic guanine α-CNP. As we had expected, 
preliminary biological evaluation was promising and, as a result, we directed our synthetic 
efforts towards enantiopure material. The commercial availability of both enantiomers of 
allylic acetate 10 now encouraged us to revisit routes from this starting material, and 
literature precedent for coupling of 10 with 2-amino-6-chloropurine
15
 offered a means of 
introducing the base at the first step (Figure 4, Route III), in line with the racemic synthesis. 
We chose to develop this route first using racemic 10. 
In the past we have used a well-established route to the acetate 10 which involves the 
palladium catalyzed ring-opening of cyclopentadiene mono-epoxide 17 with acetic acid 
(Scheme 2).
16,17
 Now we desired to use an alternative route to avoid both the tedious process 
of cracking cyclopentadiene 18 and the time-consuming distillation of the epoxide 17. The 
acid-promoted rearrangement of furfuryl alcohol 19 to the hydroxyenone has been described 
several times by means of batch- or flow-based processes.
18-21
 In a batch reaction at a 0.3 mol 
scale, we found that the hydroxyenone 20 can easily be isolated in 40% yield (11 g per batch) 
following trivial workup. 
Scheme 2. Synthesis of acetate 10 
 
The cis-selective reduction of protected derivatives of 20 has also been described,
18
 and in 
fact the reduction of the unprotected enone, using modified Luche conditions, has been 
reported to afford 9:1 cis/trans selectivity;
22
 importantly, crude 20 can be used without any 
purification, and the cis and trans diastereomers of 21 can be separated by chromatography. 
The very high water solubility of the diol means that aqueous workup is impractical and thus 
purification is hampered by the presence of the excess CeCl3 required for the best selectivity. 
On a small scale, the reported procedure works well (quench the reaction with silica gel and 
column the residue directly) but on a scale of a few grams, this proves difficult due to the 
relatively large volume of silica required, and the very large volumes of solvents 
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(CH2Cl2/MeOH) required to fully elute the product. Care must be taken to avoid using too 
much methanol in the eluent as this carries through significant amounts of cerium chloride. 
The problem was conveniently solved by using deactivated alumina to adsorb the crude 
product, followed by a preliminary plug column on deactivated alumina prior to 
chromatography on silica gel. Following this work-up the desired cis diol 21 can be isolated 
in >50% yield on a 5 g scale. With convenient access to the diol, the monoacetate is readily 
prepared in 50–65% yield following a literature procedure.
23
 In practice this route provides 
straightforward access to multi-gram quantities of the monoacetate 10; the overall yield 
starting from furfuryl alcohol is typically 14%. The diacetate side-product formed in the 
acetylation reaction can be recycled to the diol, or used as a substrate for enzymatic 
hydrolysis to provide enantioenriched 10, thereby enabling full product utilization. 
Coupling of 10 with 2-amino-6-chloropurine in the presence of 
tetrakis(triphenylphosphine)palladium(0), following literature protocol for exclusive N9-
insertion,
15
 afforded the N9-product 22 in 64% yield (Scheme 3). Sequential TBS and Boc 
protection of hydroxycyclopentenylpurine 22 provided 23 and 24 in yields of 72% and 90%, 
respectively, then treatment of 24 with TBAF released the allylic alcohol 25 (91%) required 
for the key O–H insertion reaction. Reaction of 25 with trimethyl phosphonodiazoacetate in 
refluxing benzene, in the presence of rhodium acetate dimer, afforded the unsaturated 
nucleoside phosphonate 26 in 60% yield. Catalytic hydrogenation of the cyclopentenyl 
double bond proved problematic with this substrate using palladium on carbon, but was 
readily achieved with rhodium on alumina to provide the protected nucleoside phosphonate 
16, which confirmed the regioselectivity of the Tsuji–Trost reaction.
24
 Finally, reaction of 16 
with TMSBr in the microwave followed by treatment with aqueous sodium hydroxide, as 
before, conveniently removed all protecting groups and converted the chloropurine to 
guanine to give the racemic guanine α-CNP 9, as an equimolar mixture of diastereomers, in 
83% yield following charcoal chromatography.  
Scheme 3. Synthesis of (±)-G-α-CNP via allylic substitution  
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The strategy of introducing the base before the phosphonate moiety, this time starting from 
the allylic acetate 10 (Figure 4, Route III), once again proved successful. As anticipated, 
carrying out the key O–H insertion reaction with the allylic alcohol 25 was more efficient 
(60%) than when the cyclopentyl alcohol 15 was employed (30%), facilitating good yields for 
the introduction of both the base and the phosphonate moiety, and allowing preparation of 
gram quantities of racemic guanine α-CNP 9. This methodology offers an effective route to 
the previously elusive guanine α-CNP which is applicable to both racemic and enantiopure 
syntheses, making it the route of choice to G-α-CNP. 
Having optimised the synthesis of racemic guanine α-CNP we turned our attention to 
enantiopure material. The commercial availability of both enantiomers of allylic acetate 10 
allowed parallel syntheses of both antipodes of 9 (each as a pair of diastereomers); 
accordingly, the L-isomer of G-α-CNP (−)-9 was prepared from (−)-10 via the above route 
and the D-isomer (+)-9 was obtained from the enantiomeric acetate (+)-10 (Figure 5). Yields, 
in each case, were similar to those obtained for the racemate, and optical rotation values for 
the D- and the L-series were mutually opposite in sign throughout the synthetic sequences. 
Our original report assigned (D)- and (L)-G-α-CNP as (−) and (+) respectively,
9
 based on 
optical rotations recorded in aqueous THF. We now find that more reproducible optical 
rotation values for 9 can be obtained in aqueous sodium hydroxide solution and, therefore, in 
this solvent (D)-G-α-CNP is assigned as (+)-9 and (L)-G-α-CNP is assigned as (−)-9. Access 
to both antipodes of G-α-CNP enabled biological evaluation of each pair of diastereomers. 
Interestingly, the L-isomer showed potent activity against HIV-1 RT whereas both the D- and 
the L-isomer were active against herpes virus DNA polymerases, identifying G-α-CNP as a 
direct inhibitor of multiple viral DNA polymerases.
9
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Figure 5. Diastereomers of G-α-CNP obtained from enantiopure synthesis 
In conclusion, we have developed a convenient, multi-gram scale preparation of the widely 
used cyclopentene building block, allylic acetate 10. By reversing the order of key steps in 
our original route to α-CNPs we have now synthesised the biologically active guanine 
analogue G-α-CNP 9 in good yield, in racemic and both enantiopure forms from 10. Base 
construction was also shown to be a viable route to racemic 9. These complementary 
methodologies (Figure 4, Route I, II and III) offer scope for further diversification and access 
to modified α-CNPs.  
Experimental Section. 
General information. Solvents were distilled prior to use as follows: dichloromethane was 
distilled from phosphorus pentoxide; ethyl acetate was distilled from potassium carbonate; 
tetrahydrofuran was distilled from sodium benzophenone. Solvents were degassed, as 
required, by purging with nitrogen. Organic phases were dried using anhydrous magnesium 
sulfate. Microwave reactions were carried out using a CEM Discover S-Class in conjunction 
with Synergy software. Sealed vials (10 mL or 35 mL) were used and temperature was 
measured externally using an IR sensor. Unless otherwise stated, reactions were heated using 






P NMR spectra were recorded at 20 °C on 300, 400, 500 or 600 
MHz spectrometers. Chemical shifts are given in ppm relative to TMS as an internal 
standard. 
31
P chemical shifts are referenced to H3PO4 (external standard). Coupling constants 
(J) are given in hertz (Hz). The integration of 
1
H NMR spectra was used to determine the 
diastereomer ratios of α-CNP compounds. In some cases the signal for the PCH was not 
observed in the 
13
C NMR spectrum. Optical rotations were measured at 20 °C at 589 nm in a 







. High resolution mass spectra (HRMS) were recorded on a Time of Flight 
spectrometer in electrospray ionization (ESI) mode. Column chromatography was carried out 
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using silica gel 60 unless otherwise stated. Thin layer chromatography (TLC) was carried out 
on pre-coated silica gel plates (Merck 60 PF254); visualisation was achieved by UV (254 nm) 
detection and/or staining with vanillin, ceric ammonium molybdate, or potassium 
permanganate. Charcoal chromatography was carried out using activated carbon Darco G-60, 
according to the procedure described previously.
25
 Tetrakis(triphenylphosphine)palladium(0) 
was prepared as described in the literature.
26
 
Synthesis of Racemic G-α-CNP 9 from amino alcohol 11 
Cis-3-Aminocyclopentanol (11). 3-Cbz-Aminocyclopentanol was prepared according to 
published procedures.
27
 Flash chromatography of the cis/trans mixture, eluting with 95:5, 
DCM:MeOH afforded cis-3-Cbz-aminocyclopentanol as a white solid; δH (400.1 MHz, 
CDCl3) 1.52–1.89 (4H, m), 1.90–2.28 (3H, m), 4.04–4.23 (1H, m), 4.30–4.45 (1H, m), 5.08 
(2H, s), 5.45 (1H, s), 7.24–7.44 (5H, m); δC {
1
H} (100.6 MHz, CDCl3) 31.7, 34.3, 42.3, 51.5, 
66.5, 73.1, 128.0, 128.5, 136.7, 155.8; HRMS (ES+) m/z: [M+H]
+
 Calcd for C13H18NO3 
236.1287; Found 236.1284. To a solution of cis-3-Cbz-aminocyclopentanol (377 mg, 1.6 
mmol) in methanol (20 mL) was added 5% palladium on carbon (110 mg, 5.5 mg, 3 mol %) 
and the mixture was stirred under a balloon of hydrogen overnight. After filtration through 
Celite and washing with MeOH (20 mL) then DCM (10 mL), concn of the filtrate under 
reduced pressure afforded the title compound 11 as an oil in 88% yield (143 mg); δH (400.1 
MHz, CDCl3) 1.53–2.00 (6H, m), 2.02–2.84 (3H, m), 3.59–3.72 (1H, m), 4.20–4.32 (1H, m); 
δC {
1
H} (100.6 MHz, CDCl3) 33.0, 34.8, 43.8, 52.2, 74.4; HRMS (ES+) m/z: [M+H]
+
 Calcd 
for C5H12NO 102.0919; Found 102.0916. 
2-Amino-6-chloro-9-(cis-3′-hydroxycyclopentyl)purine (12). Freshly prepared amino alcohol 
11 (143 mg, 1.4 mmol) was dissolved in 1:1 EtOH:H2O (8 mL) in a 35 mL microwave vial 
and 2-amino-4,6-dichloro-5-formamidopyrimidine (351 mg, 1.7 mmol, 1.2 eq) then Hünig’s 
base (472 µL, 350 mg, 2.7 mmol, 1.9 eq) was added. The resulting cream suspension was 
subjected to microwave irradiation at 140 °C for 90 min. Removal of the solvent afforded a 
crude red oil which was purified by flash chromatography, eluting with 2:98 to 5:98 
MeOH:EtOAc, to provide 257 mg (72%) of the title compound 12 as a white foam; δH (300.1 
MHz, CDCl3) 1.67–1.87 (1H, m), 1.96–2.15 (2H, m), 2.24–2.39 (2H, m), 2.52 (1H, ddd, J = 
15.5, 10.7, 5.5), 4.40–4.53 (1H, m), 4.78–4.93 (1H, m), 5.27 (1H, d, J = 6.4), 5.58 (2H, s), 
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7.98 (1H, s); δC {
1
H} (75.5 MHz, CDCl3) 30.6, 35.4, 41.2, 54.7, 72.2, 125.8, 142.6, 151.6, 
152.5, 158.4; HRMS (ES+) m/z: [M+H]
+
 Calcd for C10H13N5OCl 254.0809; Found 254.0798.  
2-Amino-6-chloro-9-(cis-3′-tert-butyldimethylsilyloxycyclopentyl)purine (13). Alcohol 12 
(314 mg, 1.2 mmol), tert-butyldimethylchlorosilane (280 mg, 1.9 mmol, 1.5 eq) and 
imidazole (211 mg, 3.1 mmol, 2.5 eq) were dissolved in anhydrous DMF (1.5 mL) under 
nitrogen and the solution was stirred at rt for 18 h. It was poured into brine (80 mL) and 
extracted with EtOAc (3 × 35 mL). The combined organic layers were washed with brine (80 
mL), dried over MgSO4 and concd under reduced pressure to afford the crude product, which 
was subjected to flash chromatography, eluting with 1:1, hexane: EtOAc, to provide 320 mg 
(70%) of the title compound 13 as a white solid; δH (400.1 MHz, CDCl3) 0.107 (3H, s), 0.113 
(3H, s), 0.93 (9H, s), 1.76–1.98 (3H, m), 2.01–2.16 (1H, m), 2.27–2.51 (2H, m), 4.42–4.51 
(1H, m), 4.93–5.13 (3H, m), 8.22 (1H, s); δC {
1
H} (100.6 MHz, CDCl3) −4.8, −4.7, 18.1, 
25.9, 32.3, 35.5, 42.9, 52.8, 72.9, 125.3, 142.1, 151.0, 153.7, 158.8; HRMS (ES+) m/z: 
[M+H]
+
 Calcd for C16H27N5OClSi 368.1673; found 368.1662. 
2-bis-Boc-Amino-6-chloro-9-(cis-3′-tert-butyldimethylsilyloxycyclopentyl)purine (14). 
Aminopurine 13 (120 mg, 0.3 mmol) and DMAP (3 mg, 7.5 mol %) were dissolved in 
anhydrous THF (5 mL) and Boc2O (209 mg, 220 µL, 0.9 mmol) was added. The solution was 
stirred under nitrogen for 18 h then concd under reduced pressure and the residue subjected to 
flash chromatography, eluting with 6:4, hexane: EtOAc, to provide 163 mg (88%) of the title 
compound 14 as a sticky white solid; δH (400.1 MHz, CDCl3) 0.12 (3H, s), 0.13 (3H, s), 0.94 
(9H, s), 1.45 (18H, s), 1.79–2.03 (3H, m), 2.04–2.18 (1H, m), 2.36–2.56 (2H, m), 4.46–4.57 
(1H, m), 5.15–5.28 (1H, m), 8.63(1H, s); δC {
1
H} (100.6 MHz, CDCl3) −4.85, −4.72, 18.1, 
25.9, 27.9, 32.6, 35.5, 43.0, 53.6, 73.0, 83.5, 130.0, 145.9, 150.7, 150.8, 151.6, 152.6; HRMS 
(ES+) m/z: [M+H]
+
 Calcd for C26H43N5O5ClSi 568.2722; Found 568.2726. 
2-bis-Boc-Amino-6-chloro-9-(cis-3′-hydroxycyclopentyl)purine (15). Purine 14 (425 mg, 0.7 
mmol) was dissolved in anhydrous THF (10 mL) under nitrogen and ice-cooled. A solution 
of TBAF in THF (1 M, 820 µL, 0.8 mmol) was added and the reaction was stirred in ice for 
40 min and then for 50 min with cooling removed. The solvent was removed under reduced 
pressure and the residue subjected to flash chromatography, eluting with 5:95, MeOH: DCM, 
to provide 310 mg (91%) of the title compound 15 as a white solid; δH (300.1 MHz, CDCl3) 
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1.46 (18H, s), 1.78–1.96 (1H, m), 1.97–2.16 (2H, m), 2.18–2.48 (2H, m), 2.49–2.64 (1H, m), 
3.04 (1H, d, J = 4.0), 4.54 (1H, s), 5.03–5.19 (1H, m), 8.48 (1H, s); δC {
1
H} (100.6 MHz, 
CDCl3) 27.9, 31.7, 35.4, 41.7, 54.7, 72.2, 83.7, 130.4, 146.0, 150.6, 151.1, 151.4, 152.1; 
HRMS (ES+) m/z: [M+H]
+
 Calcd for C20H29N5O5Cl 454.1857; Found 454.1862. 
2-bis-Boc-Amino-6-chloro-9-(cis-3′-
(carbomethoxy(dimethylphosphono)methoxy)cyclopentyl)purine (16). Alcohol 15 (310 mg, 
0.68 mmol) was dissolved in degassed benzene (5 mL) then trimethyl phosphonodiazoacetate 
(156 mg, 0.75 mmol, 1.1 eq) and activated sieves were added and the mixture was stirred 
under nitrogen for 30 min. Rhodium(II) acetate (3 mg, 1 mol %) was added and the reaction 
mixture was heated under reflux for 16 h then filtered and concd under reduced pressure. 
Flash chromatography of the residue (2:98 to 5:95, MeOH:EtOAc) afforded the title 
phosphonate 16 in 30% yield (131 mg, dr 1:1);	 δH (400.1 MHz, CDCl3) 1.45 (18H, s), 1.74–
2.33 (4H, m), 2.37–2.65 (2H, m), 3.82–3.95 (9H, m), 4.27–4.41 (1H, m), 4.42 (0.5H, d, 
JPH=19.2), 4.49 (0.5H, d, JPH=20.2), 5.17–5.35 (1H, m), 8.74 (0.5H, s), 8.90 (0.5H, s); δC 
{
1
H} (75.5 MHz, CDCl3) 27.9, 30.8, 31.6, 31.96, 32.02, 40.22, 40.32, 53.1, 54.0-54.4, 73.7 
(d, JPC = 160.4), 74.5 (d, JPC = 159.5), 82.0 (d, JPC = 11.6), 83.0 (d, JPC = 8.7), 83.6, 129.95, 
129.99, 145.9, 146.2, 150.68, 150.69, 150.8, 151.5, 152.7, 167.6 (d, JPC = 2.1), 167.9 (d, JPC 
= 2.8); δP (121.5 MHz, CDCl3) 16.57, 16.78; HRMS (ES+) m/z: [M+H]
+
 Calcd for 
C25H38N5O10ClP 634.2045; Found 634.2030. 
9-(cis-3′-(Carboxy(phosphono)methoxy)cyclopentyl)guanine (9). Phosphonopurine 16 (57 
mg, 0.09 mmol) was suspended in acetonitrile (2 mL) in a 10 mL microwave vial, TMSBr 
(119 µL, 138 mg, 0.9 mmol) was added and the reaction mixture was subjected to microwave 
irradiation at 50 °C for 20 min. MeOH (2 mL), containing 3 drops of water, was added and 
the orange solution was stirred for 30 min. After removal of the solvent under reduced 
pressure, 1 M sodium hydroxide (1.4 mL, 1.4 mmol) was added and the resulting solution 
was stirred at 55 °C for 22 h. Removal of the solvent under reduced pressure afforded a 
residue which was subjected to charcoal column chromatography eluting with ammonia (30% 
aq.) to provide 29 mg of 9 as a cream solid (76% as the ammonium salt, dr 1:1);		δH (400.1 
MHz, D2O) 1.08–2.00 (4H, m), 2.00–2.14 (1H, m), 1H 2.40–2.50 (1H, m), 3.93 (0.5H, d, J = 
18.2), 3.99 (0.5H, d, J = 18.3) 4.03–4.10 (1H, m), 4.51–4.62 (1H, m), 8.03 (0.5H, s), 8.04 
(0.5H, s); δC {
1
H} (125.8 MHz, D2O) 29.4, 30.5, 30.6 (2 × CH2), 37.8, 38.8 (CH2), 53.3, 53.5 
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(CH-1′), 80.0, 80.5 (CH-3′), 115.8 (C-5), 138.8 (CH-8), 151.2 (C-4), 153.4 (C-6), 158.8, 
158.9 (C-2), 177.6 (CO2H); δP (162.0 MHz, D2O) 12.36, 12.48; HRMS (ES+) m/z: [M+H]
+
 
Calcd for C12H17N5O7P 374.0866; Found 374.0861. 
Synthesis of Racemic G-α-CNP 9 from acetate 10 
4-Hydroxy-2-cyclopenten-1-one (20). A solution of furfuryl alcohol (26 mL, 0.3 mol) and 
KH2PO4 (2g, 14.7 mmol) in water (500 mL) was purged with nitrogen gas for 2 h before 
being placed in a pre-equilibrated 125 °C heating block and stirred for 48 h. After being 
cooled to rt the mixture was washed with DCM (3 × 50 mL). The washings were back-
extracted once with water (50 mL) and the combined aqueous phases were evaporated under 
reduced pressure. The residue was taken with DCM (100 mL), dried with MgSO4, filtered 
and concd to afford the hydroxy enone 20 as an amber colored oil (11.3 g, 40%) which could 
be used without purification; δH (400.1 MHz, CDCl3) 2.29 (1H, dd, J = 18.5, 1.8), 2.79 (1H, 
dd, H = 18.5, 6.1), 5.03–5.12 (1H, m), 6.20–6.29 (1H, m), 7.55–7.65 (1H, m). 
cis-1,4-Dihydroxy-2-cyclopentene (21). A solution of the enone 20 (5.0 g, 51 mmol) and 
CeCl3.7H2O (40 g, 107 mmol) in MeOH (150 mL) was cooled to an internal temperature of –
40 °C and stirred while powdered NaBH4 (2.0 g, 53 mmol) was added in small portions 
during about 30 min. After the addition the solution was allowed to warm slowly to rt 
overnight. Deactivated alumina (10% v/v H2O, 90 g) was added and the mixture was 
evaporated to dryness under reduced pressure. The residue was eluted over a plug of 
deactivated alumina (10% v/v H2O, 150 g) using 5% MeOH/DCM to afford the crude 
product which was purified by flash chromatography on silica gel, eluting with 5% 
MeOH/DCM to afford the cis-diol 21 as a colorless, fern-like solid (2.8 g, 55%); δH (400.1 
MHz, MeOD) 1.44 (1H, dt, J = 13.5, 5.4), 2.75 (1H, dt, J = 13.5, 7.3), 4.60 (2H, m), 5.92 
(2H, br s). 
cis-4-Acetoxy-2-cyclopenten-1-ol (10). A solution of the cis-diol 21 (2.8 g, 28 mmol), 
DMAP (0.34 g, 0.28 mmol) and acetic anhydride (3.0 mL, 3.24 g, 31.7 mmol) in DCM (75 
mL) was stirred overnight at ambient temperature. The mixture was concd under reduced 
pressure and the residue was purified by flash chromatography (SiO2, 1:1 EtOAc/Hexanes) to 
afford the desired mono acetate 10 as a white solid (2.5 g, 64%); δH (400.1 MHz, CDCl3) 
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1.66 (2H, dt, J = 14.7, 3.7), 1.88 (1H, br s), 2.06 (3H, s), 2.81 (1H, dt, J = 14.7, 7.4) 4.67–
4.77 (1H, m), 5.46–5.55 (1H, dd, J = 7.4, 3.7), 5.96–6.03 (1H, m), 6.09–6.15 (1H, m). Earlier 
fractions from the column afforded the diacetate as a colorless oil (1.1 g, 21%); δH (400.1 
MHz, CDCl3)1.75 (1H, dt, J = 15.0, 3.8), 2.07 (6H, s), 2.89 (1H, dt, J = 15.0, 7.6), 5.55 (2H, 
dd, J = 7.6, 3.8), 6.10 (2H, s). 
2-Amino-6-chloro-9-(cis-4′-hydroxycyclopent-2′-enyl)purine
 
(22). To a suspension of 2-
amino-6-chloropurine (1.31 g, 7.7 mmol) in anhydrous DMF (18 mL) under nitrogen was 
added sodium hydride (60% dispersion in mineral oil, 0.31 g, 7.7 mmol) to afford a clear 
solution, which was stirred at 60 °C for 1 h. A solution of cis-4-acetoxy-2-cyclopenten-1-ol 
10 (1.0 g, 7.0 mmol), tetrakis(triphenylphosphine)palladium(0) (0.41 g, 5 mol %) and 
triphenylphosphine (0.28 g, 15 mol %) in anhydrous THF (15 mL) was stirred in the dark for 
15 min then added to the DMF solution. Thereafter, the reaction mixture was stirred in the 
dark at 60 °C for 18 h then concd under reduced pressure and the residue slurried in DCM 
and filtered through Celite. The filtrate was concd under reduced pressure and the residue 
subjected to flash chromatography, eluting firstly with 1:1, hexane: EtOAc then EtOAc and 
finally 5:95, MeOH:EtOAc, to afford alcohol 22 as a white solid (1.13 g, 64%); δH (400.1 
MHz, DMSO-d6) 1.67 (1H, dt, J = 14.0, 4.3), 2.85 (1H, dt, J = 14.0, 7.7), 4.67–4.76 (1H, m), 
5.27-5.34 (1H, m), 5.35 (1H, d, J = 6.1), 5.96–6.02 (1H, m), 6.15–6.23 (1H, m), 6.86 (2H, s), 
8.02 (1H, s); δC {
1
H} (100.6 MHz, DMSO-d6) 41.0, 56.9, 73.6, 123.5, 130.4, 139.6, 141.3, 
149.4, 153.4, 159.6; HRMS (ES+) m/z: [M+H]
+




2-Amino-6-chloro-9-(cis-4′-tert-butyldimethylsilyloxycyclopent-2′-enyl)purine (23). Alcohol 
22 (1.13 g, 4.5 mmol), imidazole (0.76 g, 11.2 mmol) and tert-butyldimethylsilyl chloride 
(1.02 g, 6.8 mmol) were dissolved under nitrogen in anhydrous DMF (4.5 mL) and the 
resulting solution was stirred for 17 h. Thereafter, it was poured into brine (200 mL) and 
extracted with EtOAc (3 × 120 mL). The combined organic extracts were washed with brine 
(300 mL), dried over MgSO4 and concd under reduced pressure to afford the crude product. 
Purification by flash chromatography (1:1, hexane: EtOAc) provided 1.18 g (72%) of the title 
compound 23 as a white solid; δH (400.1 MHz, CDCl3) 0.10 (3H, s), 0.13 (3H, s), 0.91 (9H, 
s), 1.81 (1H, dt, J = 14.4, 3.0), 2.87 (1H, dt, J = 14.4, 7.3), 4.84–4.92 (1H, m), 5.19 (2H, s), 
5.41–5.50 (1H, m), 5.90–5.98 (1H, m), 6.15–6.23 (1H, m), 8.02 (1H, s); δC {
1
H} (100.6 MHz, 
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CDCl3) −4.78, −4.66, 18.1, 25.8, 41.9, 56.7, 75.2, 125.4, 130.9, 139.4, 141.7, 151.1, 153.3, 
158.9; HRMS (ES+) m/z: [M+H]
+
 Calcd for C16H25N5OClSi 366.1517; Found 366.1516. 
2-bis-Boc-Amino-6-chloro-9-(cis-4′-tert-butyldimethylsilyloxycyclopent-2′-enyl)purine (24). 
Aminopurine 23 (1.18 g, 3.2 mmol) and DMAP (39 mg, 0.3 mmol, 10 mol %) were dissolved 
in anhydrous THF (15 mL) under nitrogen and Boc2O (2.1 g, 2.2 mL, 9.6 mmol) was added. 
The solution was stirred at RT for 4.5 days then concd under reduced pressure. Flash 
chromatography of the residue (6:4, hexane: EtOAc) afforded 1.65 g (90%) of the title 
compound 24 as a white foam; δH (300.1 MHz, CDCl3) 0.11 (3H, s), 0.14 (3H, s), 0.91 (9H, 
s), 1.47 (18H, s), 1.85 (1H, dt, J = 14.6, 2.5), 2.87 (1H, ddd, J = 14.8, 8.2, 6.8), 4.87–4.96 
(1H, m), 5.60–5.70 (1H, m), 5.96–6.03 (1H, m), 6.21–6.29 (1H, m), 8.40 (1H, s); δC {
1
H} 
(75.5 MHz, CDCl3) −4.83, −4.67, 18.0, 25.8, 27.9, 41.9, 57.5, 75.1, 83.6, 130.1, 130.6, 139.9, 
145.5, 150.7, 151.0, 151.8, 152.2; HRMS (ES+) m/z: [M+H]
+
 Calcd for C26H41N5O5ClSi 
566.2566; Found 566.2551. 
2-bis-Boc-Amino-6-chloro-9-(cis-4′-hydroxycyclopent-2′-enyl)purine (25). Unsaturated 
purine 24 (1.62 g, 2.9 mmol) was dissolved in anhydrous THF (20 mL) under nitrogen and 
ice-cooled. TBAF (1 M soln in THF, 3.1 mL, 3.1 mmol) was added and the solution was 
stirred in ice for 30 min then cooling was removed and stirring was continued for a further 90 
min. After brief removal of the solvent under reduced pressure the residue was diluted with 
water (300 mL) and extracted with EtOAc (3 × 300 mL). The combined organic extracts were 
dried and concd to give the crude product which was subjected to flash chromatography 
(EtOAc) to afford alcohol 25 as a white foam (1.18 g, 91%); δH (400.1 MHz, CDCl3) 1.47 
(18H, s), 2.05–2.15 (1H, m), 3.05 (1H, overlapping dt, J = 15.8, 7.9), 3.72-3.82 (1H, m), 
4.87–4.97 (1H, m), 5.43–5.52 (1H, m), 5.88–5.95 (1H, m), 6.32–6.39 (1H, m), 8.24 (1H, s); 
δC {
1
H} (100.6 MHz, CDCl3) 27.9, 40.2, 59.8, 75.2, 83.9, 129.9, 131.0, 140.2, 145.6, 150.4, 
151.3, 151.5, 151.8; HRMS (ES+) m/z: [M+H]
+
 Calcd for C20H27N5O5Cl 452.1701; Found 
452.1706. 
2-bis-Boc-Amino-6-chloro-9-(cis-4′-(carbomethoxy(dimethylphosphono)methoxy)cyclopent-
2′-enyl)purine (26). Alcohol 25 (1.15 g, 2.5 mmol) and trimethyl phosphonodiazoacetate (634 
mg, 3.0 mmol) were suspended in degassed benzene (12 mL), activated sieves were added 
and the mixture was stirred under nitrogen for 75 min. The mixture was inserted into a heated 
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block at 95 °C then rhodium(II) acetate (22 mg, 2 mol %) was added and the reaction mixture 
was heated under reflux overnight. After 16 h a second portion of catalyst (11 mg, 1 mol %) 
was added and reflux was continued for a further 4 h then the reaction mixture was filtered 
and concd under reduced pressure. Flash chromatography of the residue (EtOAc to 5:95, 
MeOH:EtOAc) afforded phosphonate 26 as a fawn foam in 60% yield (0.97 g, dr 1:1);	δH 
(500.1 MHz, CDCl3) 1.47 (18H, 2 closely spaced s), 2.05–2.18 (1H, m), 2.85–2.98 (1H, m), 
3.78–3.93 (9H, m), 4.49 (0.5H, d, JPH=25.4), 4.53 (0.5H, d, JPH=24.9), 4.72–4.83 (1H, m), 
5.67–5.75 (1H, m), 6.14–6.20 (1H, m), 6.41–6.48 (1H, m), 8.44 (0.5H, s), 8.48 (0.5H, s); δC 
{
1
H} (125.8 MHz, CDCl3) 27.9, 38.3, 38.6, 53.07, 53.11, 54.1-54.4, 57.05, 57.13, 74.94 (d, 
JPC = 159.6), 74.96 (d, JPC = 159.6), 83.69, 83.70, 84.5 (d, JPC = 10.2), 84.7 (d, JPC = 11.4), 
130.1, 133.8, 134.2, 135.9, 136.4, 145.3, 145.5, 150.74, 150.76, 151.1, 151.8, 152.2, 167.5 (d, 
JPC = 2.5), 167.7 (d, JPC = 2.5); δP (121.5 MHz, CDCl3) 16.1, 16.3; HRMS (ES+) m/z: 
[M+H]
+
 Calcd for C25H36N5O10ClP 632.1888; Found 632.1877.  
2-bis-Boc-Amino-6-chloro-9-(cis-3′-
(carbomethoxy(dimethylphosphono)methoxy)cyclopentyl)purine (16). Phosphonate 26 (1.25 
g, 2.0 mmol) was dissolved in MeOH (15 mL), 5% Rh on alumina (250 mg, 12.5 mg, 6 mol 
%) was added and the reaction mixture was stirred under a balloon of hydrogen for 5 h then 
filtered through Celite, washing with MeOH (100 mL) and DCM (100 mL). The combined 
filtrate was concd and the residue subjected to flash chromatography (EtOAc - 5:95, 
MeOH:EtOAc) to provide 0.95 g (75%, dr 1:1) of phosphonate 16 as a white foam, identical 
spectroscopically to 16 prepared above. 
9-(cis-3′-(Carboxy(phosphono)methoxy)cyclopentyl)guanine (9). Phosphonopurine 16 (355 
mg, 0.6 mmol) was suspended in acetonitrile (2 mL) in a 10 mL microwave vial, TMS 
bromide (740 µL, 857 mg, 5.6 mmol) was added and the reaction mixture was subjected to 
microwave irradiation at 50 °C for 20 min. MeOH (2 mL), containing 200 µL water, was 
added to give an orange solution which was stirred for 2 h. After removal of the solvent under 
reduced pressure, 5 M sodium hydroxide (2.8 mL, 14 mmol) was added and the resulting 
solution was stirred at 55 °C for 22 h. Removal of the solvent under reduced pressure 
followed by charcoal column chromatography of the residue eluting with ammonia (30% aq.) 
provided 181 mg of 9 as a cream solid (83% yield as ammonium salt, dr 1:1). 
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Synthesis of (L)-G-α-CNP (−)-9. All products in the enantiopure series below were identical 
by 
1
H NMR to their racemic counterparts.  
(−)-(1′S,4′R)-2-Amino-6-chloro-9-(4′-hydroxycyclopent-2′-enyl)purine ((−)-22). This was 
prepared following the procedure described for 22, starting from 2-amino-6-chloropurine 
(0.66 g, 3.9 mmol) and sodium hydride (60% dispersion in mineral oil, 0.15 g, 3.52 mmol) in 
anhydrous DMF (12 mL), and (1R,4S)-cis-4-acetoxy-2-cyclopenten-1-ol (−)-10 (0.50 g, 3.5 
mmol), tetrakis(triphenylphosphine)palladium(0) (0.20 g, 0.17 mmol, 5 mol %) and 
triphenylphosphine (0.14 g, 0.53 mmol, 15 mol %) in anhydrous THF (15 mL). The product 
(−)-22 was isolated as a white powder, yield 0.48 g (54%); []




 – 11.5 (c 0.54, MeOH)]. 
(−)-(1′S,4′R)-2-Amino-6-chloro-9-(4′-tert-butyldimethylsilyloxycyclopent-2′-enyl)purine 
((−)-23). This was prepared following the procedure described for 23, starting from (−)-22 
(0.45 g, 1.8 mmol), imidazole (0.27 g, 4.0 mmol) and tert-butyldimethylsilyl chloride (0.33 g, 
2.2 mmol) in anhydrous DMF (2 mL). The product (−)-23 was isolated as a fluffy white 
solid, yield 0.50 g (76%); []
 – 3.2 (c 0.60, CHCl3). 
(−)-(1′S,4′R)-2-bis-Boc-Amino-6-chloro-9-(4′-tert-butyldimethylsilyloxycyclopent-2′-
enyl)purine ((−)-24). This was prepared following the procedure described for 24, starting 
from the aminopurine (−)-23 (0.55 g, 1.5 mmol), DMAP (18 mg, 0.15 mmol, 10 mol %) and 
Boc2O (1.03 mL, 0.98 g, 4.5 mmol) in anhydrous THF (7 mL). The product (−)-24 was 
isolated as a white foam, yield 0.73 g (86%); []
 – 11 (c 1.11, CHCl3).  
(−)-(1′S,4′R)-2-bis-Boc-Amino-6-chloro-9-(4′-hydroxycyclopent-2′-enyl)purine ((−)-25). 
This was prepared following the procedure described for 25, starting from the bis-boc-
aminopurine (−)-24 (0.73 g, 1.3 mmol) and TBAF (1M in THF, 1.4 mL, 1.4 mmol) in 
anhydrous THF (9 mL). The product (−)-25 was isolated as a fluffy white solid, yield 0.55 g 
(93%); []
 – 93 (c 1.05, CHCl3). 
(+)-(1′S,4′R)-2-bis-Boc-Amino-6-chloro-9-(4′-
(carbomethoxy(dimethylphosphono)methoxy)cyclopent-2′-enyl)purine ((+)-26). This was 
prepared following the procedure described for 26, starting from the alcohol (−)-25 (0.55 g, 
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1.2 mmol), trimethyl diazophosphonoacetate (0.30 g, 1.4 mmol) and rhodium(II) acetate (11 
mg, 2 mol%) in benzene (10 mL). A second portion of catalyst (8 mg, 1.5 mol%) was added 
after 16h and heating under reflux was continued for a further 90 min thereafter. The product 
(+)-26 was isolated as a foamy solid, yield 0.46 g (60%, dr 1:1); []
 2.4 (c 0.91, CHCl3). 
(+)-(1′R,3′S)-2-bis-Boc-Amino-6-chloro-9-(3′-
(carbomethoxy(dimethylphosphono)methoxy)cyclopentyl)purine ((+)-16). This was prepared 
following the procedure described for 16, starting from the phosphonate (+)-26 (0.46 g, 0.7 
mmol) and 5% Rh on alumina (90 mg, 4.5 mg, 6 mol %) in MeOH (6 mL). The product (+)-
16 was isolated as a foamy solid, yield 0.33 g (72%, dr 1:1); []
 15 (c 0.95, CHCl3). 
(−)-(1′R,3′S)-9-(3′-(Carboxy(phosphono)methoxy)cyclopentyl)guanine ((−)-9). This was 
prepared following the microwave procedure described for 9, starting from the phosphonate 
(+)-16 (333 mg, 0.5 mmol) and TMSBr (693 µL, 804 mg, 5.2 mmol) in acetonitrile (2 mL), 
followed by stirring in methanol (2 mL) containing water (200 µL), and finally by warming 
in 5 M sodium hydroxide (3.1 mL, 15.7 mmol). The product (−)-9 was obtained as a cream 
solid after charcoal chromatography eluting with ammonia (30% aq.), yield 159 mg (77% as 
the ammonium salt, dr 1:1); []
 −3.5 (c 0.51, 0.1M NaOH). 
Synthesis of (D)-G-α-CNP (+)-9. All products in the enantiopure series below were identical 
by 
1
H NMR to their racemic counterparts.  
(+)-(1′R,4′S)-2-Amino-6-chloro-9-(4′-hydroxycyclopent-2′-enyl)purine ((+)-22). This was 
prepared following the procedure described for 22, starting from 2-amino-6-chloropurine 
(0.66 g, 3.9 mmol) and sodium hydride (60% dispersion in mineral oil, 0.15 g, 3.52 mmol) in 
anhydrous DMF (12 mL), and (1S,4R)-cis-4-acetoxy-2-cyclopenten-1-ol (+)-10 (0.50 g, 3.5 
mmol), tetrakis(triphenylphosphine)palladium(0) (0.20 g, 0.17 mmol, 5 mol %) and 
triphenylphosphine (0.14 g, 0.53 mmol, 15 mol %) in anhydrous THF (15 mL). The product 
(+)-22 was isolated as a white powder, yield 0.63 g (71%); []
 26 (c 0.55, MeOH). 
(+)-(1′R,4′S)-2-Amino-6-chloro-9-(4′-tert-butyldimethylsilyloxycyclopent-2′-enyl)purine 
((+)-23). This was prepared following the procedure described for 23, starting from (+)-22 
(0.62 g, 2.5 mmol), imidazole (0.37 g, 5.5 mmol) and tert-butyldimethylsilyl chloride (0.47 g, 
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3.1 mmol) in anhydrous DMF (2.8 mL). The product (+)-23 was isolated as a fluffy white 
solid, yield 0.75 g (82%); []
 2.8 (c 0.6, CHCl3). 
(+)-(1′R,4′S)-2-bis-Boc-Amino-6-chloro-9-(4′-tert-butyldimethylsilyloxycyclopent-2′-
enyl)purine ((+)-24). This was prepared following the procedure described for 24, starting 
from the aminopurine (+)-23 (0.73 g, 2.0 mmol), DMAP (24 mg, 0.2 mmol, 10 mol%) and 
Boc2O (1.38 mL, 1.3 g, 6.0 mmol) in anhydrous THF (9 mL). The product (+)-24 was 
isolated as a white foam, yield 1.04 g (92%); []
 8.6 (c 1.14, CHCl3). 
(+)-(1′R,4′S)-2-bis-Boc-Amino-6-chloro-9-(4′-hydroxycyclopent-2′-enyl)purine ((+)-25). 
This was prepared following the procedure described for 25, starting from the bis-boc-
aminopurine (+)-24 (1.00 g, 1.8 mmol) and TBAF (1M in THF, 1.9 mL, 1.9 mmol) in 
anhydrous THF (13 mL). The product (+)-25 was isolated as a fluffy white solid, yield 0.68 g 
(84%); []
  93 (c 1.03, CHCl3). 
(−)-(1′R,4′S)-2-bis-Boc-Amino-6-chloro-9-(4′-
(carbomethoxy(dimethylphosphono)methoxy)cyclopent-2′-enyl)purine ((−)-26). This was 
prepared following the procedure described for 26, starting from the alcohol (+)-25 (0.65 g, 
1.4 mmol), trimethyl diazophosphonoacetate (0.30 g, 1.4 mmol) and rhodium(II) acetate (16 
mg, 2.5 mol%) in benzene (12 mL). A second portion of catalyst (9 mg, 1.4 mol%) was 
added after 16h and heating under reflux was continued for a further 6 h thereafter. The 
product (−)-26 was isolated as a crispy foam, yield 0.54 g (59%, dr 1:1); []
 −0.7 (c 1.01, 
CHCl3). 
(−)-(1′S,3′R)-2-bis-Boc-Amino-6-chloro-9-(3′-
(carbomethoxy(dimethylphosphono)methoxy)cyclopentyl)purine ((−)-16). This was prepared 
following the procedure described for 16, starting from the phosphonate (−)-26 (0.54 g, 0.8 
mmol) and 5% Rh on alumina (105 mg, 5.2 mg, 6 mol%) in MeOH (7 mL). The product (−)-
16 was isolated as a white solid, yield 0.35 g (65%, dr 1:1); []
 −14 (c 0.96, CHCl3). 
(+)-(1′S,3′R)-9-(3′-(carboxy(phosphono)methoxy)cyclopentyl)guanine ((+)-9). This was 
prepared following the microwave procedure described for 9, starting from the phosphonate 
(−)-16 (312 mg, 0.5 mmol) and TMSBr (650 µL, 754 mg, 4.9 mmol) in acetonitrile (2 mL), 
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followed by stirring in methanol (2 mL) containing water (200 µL), and finally by warming 
in 5 M sodium hydroxide (3mL, 15 mmol). The product (+)-9 was obtained as a cream solid 
after charcoal chromatography eluting with ammonia (30% aq.), yield 170 mg (88% as the 
ammonium salt, dr 1:1); []






C NMR spectra of all synthetic compounds described in the Experimental 
Section. Supporting information is available free of charge on the ACS Publications website 
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